DOCM.SW DocMorris AG down 12.47% intraday 21 Jan 2026 (SIX): CHF5.65 key
DOCM.SW stock slid 12.47% intraday to CHF5.65 on 21 Jan 2026 on the SIX exchange, making DocMorris AG one of the top losers in Swiss healthcare today. The move follows heavy selling with 438,564 shares traded versus an average of 338,817, a relative volume of 2.04. Intraday range hit a low of CHF5.41 and a high of CHF5.96. We break down what pushed prices lower, the near-term technical levels, valuation signals and what traders should monitor next.
DOCM.SW stock: Intraday sell-off and price action
DocMorris AG (DOCM.SW) opened at CHF5.96 and fell to CHF5.65, down CHF0.80 or 12.47% from the previous close of CHF6.455. Volume spiked to 438,564 today compared with an average of 338,817, signalling conviction behind the sell-off.
The share traded between CHF5.41 (day low) and CHF5.96 (day high). Key technical anchors: the 50-day average at CHF5.60 and the 200-day average at CHF7.98, which now acts as resistance on rebounds.
Drivers: earnings calendar, ratings and sector context
There is no new DOCM.SW stock earnings release today, but the company has an earnings announcement scheduled for 19 Mar 2026, which may amplify volatility ahead. Market attention also reflects a Jan 20 rating that listed the company as C with a Sell bias and weak DCF and profitability metrics.
Sector context matters: Swiss healthcare peers trade with higher median PE and PB ratios, and the medical-pharmaceutical group showed positive 3M performance. That gap increases focus on DocMorris’ profitability and growth trajectory.
Valuation and financials for DOCM.SW stock
DocMorris shows EPS -4.58 and an effective TTM PE of -1.29, driven by negative net income. Price to Sales is 0.27, Price to Book is 0.36, and cash per share stands at CHF7.89, giving the balance sheet partial cushion at current prices.
Liquidity ratios are solid: current ratio 3.25 and quick ratio 2.85. Leverage is moderate with debt to equity 0.65 and enterprise value CHF447.00M against a market cap of CHF286.74M.
Technicals and market structure for DOCM.SW stock
Momentum indicators show mixed signals: RSI 58.98 and MACD histogram 0.07, suggesting the down leg may be corrective rather than trend-confirming. Bollinger Bands sit at Upper 6.49 / Middle 5.78 / Lower 5.07, placing current price near the middle band.
Short-term support sits near CHF5.40–CHF5.00 and immediate resistance at CHF6.50 and the 200-day MA CHF7.98. Watch intraday volume and whether selling pressure fades below or above the CHF5.65 pivot.
Meyka AI grade and model view on DOCM.SW
Meyka AI rates DOCM.SW with a score out of 100: 59.93 (Grade C+) — HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade emphasizes weak profitability but some balance-sheet strength.
Technical readouts and the grade recommend caution: short-term trading for volatility, and a hold stance for longer-term investors until clearer earnings or structural improvements appear.
Risks and opportunities for DOCM.SW stock investors
Key risks: sustained negative net margin -11.38%, negative ROE -29.46%, high intangible assets ratio 53.69%, and historical share decline (1Y -72.58%) that points to sentiment risk. EPS remains negative at -4.58, heightening downside risk if sales growth stalls.
Opportunities: low valuation multiples (P/S 0.27, P/B 0.36), CHF7.89 cash per share and improving operating cash flow growth reported for FY2024. If management stabilises margins and delivers growth, upside to recovery targets becomes feasible.
Final Thoughts
DocMorris AG (DOCM.SW) is a top intraday loser on 21 Jan 2026 after a 12.47% fall to CHF5.65 on the SIX exchange. Traders saw above-average volume 438,564 and a clear break below the prior close, placing the CHF5.40–CHF5.00 zone as immediate support. Valuation metrics show low multiples—P/S 0.27 and P/B 0.36—but earnings are negative (EPS -4.58) and ROE is weak at -29.46%, so fundamental recovery requires profit turnaround. Meyka AI’s forecast model projects a monthly target of CHF3.72, implying a -34.16% move versus the current price; forecasts are model-based projections and not guarantees. For longer-term scenarios our working price target sits near CHF8.00, giving an implied upside of 41.59% from CHF5.65 but that outcome needs margin improvement and revenue stability. Use tight risk controls in intraday trades and watch the 19 Mar 2026 earnings date for clearer guidance. This analysis uses data from SIX-listed DOCM.SW and is provided by Meyka AI, an AI-powered market analysis platform.
FAQs
Why did DOCM.SW stock drop sharply intraday today?
DOCM.SW stock fell on heavy selling and above-average volume of 438,564, following weak sentiment and a recent market rating that flagged profitability concerns. No new earnings were reported today, but traders reacted to valuation and margin weaknesses.
What are the nearest support and resistance levels for DOCM.SW stock?
Near-term support is CHF5.40–CHF5.00 with immediate resistance at CHF6.50 and the 200-day moving average at CHF7.98. Watch volume for confirmation on any break or bounce.
How does Meyka AI rate DOCM.SW stock and what does it mean?
Meyka AI rates DOCM.SW with a score out of 100: 59.93 (C+) — HOLD. The grade factors in benchmark and sector comparisons, financial growth, key metrics and analyst signals. It is informational and not investment advice.
What is Meyka AI’s short-term forecast for DOCM.SW stock?
Meyka AI’s forecast model projects CHF3.72 on a monthly horizon, implying a -34.16% decline from the current CHF5.65. Forecasts are model-based projections and not guarantees.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
